BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
4.900
-0.140 (-2.78%)
Sep 8, 2025, 10:42 AM - Market open
BioNexus Gene Lab Revenue
BioNexus Gene Lab had revenue of $2.26M in the quarter ending June 30, 2025, with 14.47% growth. This brings the company's revenue in the last twelve months to $9.55M, up 4.01% year-over-year. In the year 2024, BioNexus Gene Lab had annual revenue of $9.51M, down -2.66%.
Revenue (ttm)
$9.55M
Revenue Growth
+4.01%
P/S Ratio
0.95
Revenue / Employee
$318,385
Employees
30
Market Cap
8.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.51M | -260.16K | -2.66% |
| Dec 31, 2023 | 9.77M | -1.16M | -10.60% |
| Dec 31, 2022 | 10.93M | -2.43M | -18.21% |
| Dec 31, 2021 | 13.36M | 1.97M | 17.31% |
| Dec 31, 2020 | 11.39M | 11.26M | 8,872.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rio Tinto Group | 53.73B |
| BHP Group | 51.26B |
| CRH plc | 36.35B |
| Linde | 33.25B |
| Freeport-McMoRan | 25.82B |
| The Sherwin-Williams Company | 23.08B |
| Newmont | 20.58B |
| Ecolab | 15.72B |
BGLC News
- 5 weeks ago - BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness - GlobeNewsWire
- 5 months ago - BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory - GlobeNewsWire
- 6 months ago - BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy - GlobeNewsWire
- 6 months ago - BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper - GlobeNewsWire
- 1 year ago - BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. - GlobeNewsWire
- 1 year ago - BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd. - GlobeNewsWire
- 1 year ago - BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions - GlobeNewsWire